Hansa Biopharma AB (STU:24H) Treasury Stock : €0.00 Mil (As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Hansa Biopharma AB Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Hansa Biopharma AB's treasury stock for the quarter that ended in Dec. 2024 was €0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Hansa Biopharma AB Treasury Stock Historical Data

The historical data trend for Hansa Biopharma AB's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hansa Biopharma AB Treasury Stock Chart

Hansa Biopharma AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Treasury Stock

Get a 7-Day Free Trial

-0.14

-0.18

-0.24

-0.21

Hansa Biopharma AB Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Treasury Stock	Get a 7-Day Free Trial															-0.21	-	-	-	-

Hansa Biopharma AB Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Hansa Biopharma AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hansa Biopharma AB (STU:24H) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

HNSA:Sweden 0RC7:UK

Address

Scheelevagen 22, Lund, SWE, 223 63

Website

https://www.hansabiopharma.com

Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in sensitized patients and further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. It operates in Sweden, other European countries, and the U.S. The group generates the majority of its revenue from product sales.

Hansa Biopharma AB Headlines

No Headlines